Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm

In this whitepaper, the Manufacturing Technical Committee of the Product Quality Research Institute provides information on the common, best practices in use today in the development of high-quality chemistry, manufacturing and controls documentation. Important topics reviewed include International Conference on Harmonization, in vitro–in vivo correlation considerations, quality-by-design approaches, process analytical technologies and current scale-up, and process control and validation practices. It is the hope and intent that this whitepaper will engender expanded dialog on this important subject by the pharmaceutical industry and its regulatory bodies.

[1]  Roger Nosal,et al.  PQLI Key Topics - Criticality, Design Space, and Control Strategy , 2008, Journal of Pharmaceutical Innovation.

[2]  Michael Levin,et al.  Supac-Mr: Modified Release Solid Oral Dosage Forms‚ÄîScale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation , 2001 .

[3]  Christopher J. Potter,et al.  PQLI Roadmap: Product Design, Development, and Realization, a Science- and Risk-Based Approach to Implementation - An Overview of ISPE's First PQLI Guide , 2010 .

[4]  F. Theeuwes,et al.  Scaleup of Oral Extended-Release Dosage Forms , 2004, Pharmaceutical Research.

[5]  Steve Figard,et al.  The Basics of Experimental Design for Multivariate Analysis , 2009 .

[6]  Keith McDonald,et al.  ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entities , 2012 .

[7]  James Cheney,et al.  Quality by design and compression , 2016 .

[8]  Michael Levin Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .

[9]  James N. Michaels,et al.  Attribute-Based Design Space: Materials-Science-Based Quality-By-Design for Operational Flexibility and Process Portability , 2011, Journal of Pharmaceutical Innovation.

[10]  Guidance for Industry PAT — A Framework for Innovative Pharmaceutical Development , Manufacturing , and Quality Assurance , 2004 .

[11]  Andre Raw,et al.  Quality by Design: Concepts for ANDAs , 2008, The AAPS Journal.

[12]  G. E. Peck,et al.  Scaleup of Immediate Release Oral Solid Dosage Forms , 2004, Pharmaceutical Research.

[13]  Michael Levin,et al.  Extended Release Oral Dosage Forms‚ÄîDevelopment,Evaluation, and Application of In Vitro/In Vivo Correlations , 2001 .

[14]  山田 哲 Guidance for Industry--Changes to an Approved NDA or ANDA , 2004 .